Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough. The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.

These and other market data and trends are presented in "Hepatitis C Virus And Therapeutics: A Global Update of Market Trends & Opportunities" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

1.Methodology
- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level
2.Global Market Overview and Outlook
- Pegylated Alpha Interferon plus Ribavirin - The Standard Therapy
- Approved Drugs for Hcv Combination Therapy
- Alpha Interferons and Ribavirin Are Here to Stay
- Interferon-Based Drugs in Pipeline by Company and Development Stage
- Albuferon - Rising above The Standards
- Viramidine - next-Generation Ribavirin Drug
- High Mutation Rates Keep Hcv Elusive
- Genotype I - Least Responsive and Most Common Variant of Hcv
- Protease Inhibitors (Pis) - Way above Others
- Protease Inhibitor Drugs in Pipeline by Company and Development Stage
- Sch 900518 - Schering's next-Generation Protease Inhibitor
- Telaprevir (Vx-950) - The Most Promising Pipeline Hcv Protease Inhibitor
- Boceprevir - Schering's Pi Class Lead Candidate
- Comparison between Telaprevir and Boceprevir
- Telaprevir and Boceprevir - A Comparison
- Polymerase Inhibitors (Plis) - Adding More Teeth to Hcv Pipeline
- Viral Polymerases
- Polymerase Inhibitor Drugs in Pipeline by Company, Category, and Development Stage
- R7128 - A Promising Pli Class Drug
- Development of Plis Remains A Challenge for Hcv Researchers
- Industry in Search of Novel Stat-C Drugs
- Specific Antiviral Activity of Select Hcv Drug Classes
- Select Ns5a Inhibitors, Entry Inhibitors, and Thiazolides in Pipeline by Company and Development Stage
- Researchers Show Continued Appetite for Immunomodulators and Other Classes
- Immunomodulators in Pipeline by Company, and Development Stage
- Adjuvant Therapies to Compete with Mainline Therapies
- Cyclophilin Analogs and Fibrosis/ Inflammation Inhibitors in Pipeline by Company
- Vaccine Development Remains at Low Scale
- Hcv Vaccines in Pipeline by Company, and Development Stage
- Decisive Factors for Success of New Hcv Therapeutics
- Hcv Treatment Costs to Escalate
- Roche & Schering - Dominant Players in Hcvtherapeutics Market
- Hcv Drugs from Roche & Schering
- Partnerships in R&d Become Order of The Day
- Select Partnership Deals in Hcv Drugdevelopment Programs
- Market Drivers/Constraints
- Treatment-Experienced Patients - A Potential Opportunity for Developers
- Education Campaigns to Magnify Patient Diagnosis Rates
- Stigmatization and Discrimination - Major Hurdles for Hcv Treatment
- Treatment with Current Therapies Plagued by Side Effects
- Hemolytic Anemia - A Key Side Effect with Ribavirin
- Epidemiology
- Quick Facts about Hcv Infection
- Low-Treatment Rates Vis-À-Vis Patient Population
- Factors Influencing Hcv Treatment Market
- Drivers
- Bottle Necks
3.Hcv Medication - Approved & Pipeline Drugs
- Approved Drugs for Hcv Treatment
- Interferons - The Backbone of Hcv Treatment
- Intron® A
- Roferon A
- Infergen
- Peg-Intron®
- Pegasys
- Fda Approval of Interferons for Use as Monotherapy in Chronic Hepatitis C Treatment
- Ribavirin - Antiviral Drug for Hcv Treatment
- Rebetol®
- Copegus
- Drugs in Pipeline for Hcv Treatment
- Select Hcv Drugs under Pipeline (Phase Iii/Phase Ii) by Company
- Select Hcv Drugs under Pipeline (Phase I) by Company
- Select Hcv Drugs in Pre-Clinical/Research Stage by Company
- Select Hcv Drugs with Cancelled Clinical Studies by Company
4.Product Facts
- Hepatitis C Virus
5.Regional Perspective
- United States
- Hcv Infection - Ethnicity
- African-Americans React Poorly to Treatment
- Genotype 1 - The Most Prevalent Hcv Strain
- Falling Hcv Incidences in The US
- Canada
- Australia
- India
- Egypt
- France
- The Netherlands
- Hcv Infection Prevalence in Risk Groups in The Netherlands
- Central and Eastern Europe
- Hcv Prevalence Rate Higher in Injection Drug Users
- Alarming Rates of Hiv/Hcv Co-Infection
- Testing and Counseling Structure Poorly Developed
- Depleted Testing Schemes for Prisoners
- Scarcity Prevails at Health Care Providers and Governments as Well
- Practical Availability of Peg-Ifn Remains Limited
- Dearth in Political Commitment
- Hcv Diagnostic Tests and Treatment in Select Cee Countries
- Bulgaria
- Czech Republic
- Hungary
- Romania
- Russia
- Ukraine
- Availability of Testing Protocols for Hcv in Select Cee Countries
6.Corporate Developments
- Three Rivers Acquires Infergen®
- International Consolidated Cos Takes over China Gene
- Hologic Signs Definitive Deal to Acquire Third Wave
- Glaxosmithkline Inks Deal to Take over Genelabs
- Biolex Signs Deal to Purchase Octoplus' Stake in Locteron®
- Orasure and Schering-Plough Form Global Alliance
- Tacere and Oncolys Sign Licensing Agreement
- Beckman Wins Hcv Diagnostics Rights from Siemens Healthcare
- Anadys Secures Fda Fast Track Designation for Its Lead Drug Candidate
- Roche Bags European Commission Approval for Combination Therapy
- Roche Receives European Commission Approval for Shortened Hepatitis C Therapy
- Itherx Establishes Advisory Board for Hepatitis C Advanced Therapeutics
- Sciclone Terminates Zadaxin®
- Vertex to Initiate Phase Iii Trial of Telaprevir
- Amarillo and Cytopharm to Initiate Phase Ii Study of Novel Oral Interferon
- Biolex Releases Locteron® Phase Iia Trial Results
- Schering-Plough Releases Details of Boceprevir Phase Ii Study
- Progenics Releases Pre-Clinical Results of Pro 206
- Zymogenetics Reveals Phase Ib Results of Il-29
- Phenomix Begins Phase Ia Study of Phx1766
- Inovio and Tripep Release Additional Interim Results for Chronvac-C®
- Intermune Starts Clinical Study of Itmn-191
- Roche and Associates Commence Clinical Trial of All-Oral Dual-Antiviral Therapy
- Globeimmune Announces Phase Ii Clinical Trials with Gi-5005
- Astrazeneca Acquires Arrow Therapeutics
- Cubist Takes over Illumigen
- China Medical to Take over Beijing Bio-Ekon
- Schering-Plough Collaborates with Orasure
- Pro-Pharmaceuticals to Collaborate with Digna Biotech
- Medivir and Tibotec Establish Collaboration Deal
- Vgx Extends Collaboration with University of Pennsylvania
- Presidio Wins Exclusive License to Novel Hcv Technology
- Roche Inks Licensing Deal with Novartis and Ortho-Clinical
- Peregrine Opens Subsidiary in China
- Intermune Completes Production Milestone
- Arrow Expands Hepatitis C Pipeline
- Roche Wins Japanese Approval for Combination Therapy
- Schering-Plough Bags European Commission Approval for Combination Therapy
- Abbott Bags Fda Approval for Screening Test
- Abbott Bags Canadian Approval for Viral Load Tests
- Phynova Bags Fda Approval for Ind Application
- Worldwide Biotech Bags Chinese Fda Approval for Hcv Diagnostic Kit
- Tibotec Applies to European Regulator to Initiate Phase I Trials
- Roche Submits Application for Novel Hepatitis C to with Fda
- Anadys Discontinues Ana975
- Cerus Bags Nih Funding for Hcv Vaccine Program
- Human Genome Gets Encouraging Interim Results with Albuferon
- Intarcia Releases Study Results of Omega Interferon
- Nautilus Biotech Commences Phase I Study for Belerofon®
- Migenix Announces Phase Ii Proof-of-Concept Study Results of Celgosivir
- Pharmasset Begins Multiple Dose-Escalating Study of R7128
- Transgene Commences Phase I Trial of Tg4040
- Debiopharm Releases Phase Ib Results of Debio 025
- Nabi Biopharmaceuticals Starts Proof-of- Concept Trial for Civacir
- Peregrine Announces Positive Results for Bavituximab
7.Major Players
- Abbott Diagnostics (USA)
- Achillion Pharmaceuticals, Inc. (USA)
- Anadys Pharmaceuticals, Inc. (USA)
- Boehringer Ingelheim Gmbh (Germany)
- Bristol-Myers Squibb Company (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Glaxosmithkline Plc (UK)
- Hayashibara Biochemical Labs, Inc. (Japan)
- Hemispherx Biopharma, Inc. (USA)
- Human Genome Sciences (USA)
- Idenix Pharmaceuticals, Inc. (USA)
- Innogenetics Nv (Belgium)
- intermune, Inc. (USA)
- Intarcia Therapeutics, Inc. (USA)
- Medivir Ab (Sweden)
- Merck & Co., Inc. (USA)
- Novartis Ag (Switzerland)
- Chiron Corporation (USA)
- Pfizer, Inc. (USA)
- Schering-Plough Corporation (USA)
- Tibotec Pharmaceuticals Ltd. (Ireland)
- Tripep Ab (Sweden)
- Toray Industries, Inc. (Japan)
- Valeant Pharmaceuticals International (USA)
- Vertex Pharmaceuticals, Inc. (USA)
Exhibitstable 1: Global Hepatitis C Virus Therapeutics Market: 2007-2015 (Sales in US$ Million)
- Table 2: Prevalence and Incidence Rate of Hcv Infected Population by Select Country in The World -
- Table 3: Annual Sales of Select Interferons & Ribavirins Offered by Major Players in The Global Hcv Therapeutics Market - 2008 (in US$ Million)
- Table 4: Hcv Infection in The US: Number of Infected People for The Year 2008 (in '000s)
- Table 5: Percentage Breakdown of Infection Sources by Medium in The US Hcv Market -
- Table 6: Hcv Prevalence by Genotype in The US - 2005 (in %)
- Table 7: Market Shares of Hcv Infection Transmission Modes in Australiacompanies Profiled

Pharmaceutical Market Research

Hepatitis C Virus and Therapeutics

Hepatitis C Virus and Therapeutics

Contents

Related products